Brief: Heidelberg Pharma And Huadong Announce Strategic Partnership, Including Equity Investment

Heidelberg Pharma AG

27/02/2022 12:29

Feb 27 (Reuters) - Heidelberg Pharma AG  HPHA.DE :
    * DGAP-ADHOC: HEIDELBERG PHARMA AND HUADONG ANNOUNCE
STRATEGIC
PARTNERSHIP, INCLUDING EQUITY INVESTMENT
    * HEIDELBERG PHARMA AG -COS ENTERED INTO A STRATEGIC
PARTNERSHIP
WITH SIGNING OF AN EXCLUSIVE LICENSING AGREEMENT AS WELL AS AN
INVESTMENT AGREEMENT
    * HEIDELBERG PHARMA AG- AGREEMENTS WERE CONCLUDED WITH
WHOLLY
OWNED SUBSIDIARIES OF HUADONG
    * HEIDELBERG PHARMA AG-GRANTS HUADONG EXCLUSIVE LICENSE TO
DEVELOP
AND COMMERCIALIZE HDP-101 AND HDP-103 IN ASIA
    * HEIDELBERG PHARMA AG- GRANTS HUADONG EXCLUSIVE OPT-IN
RIGHTS FOR
TWO MORE PIPELINE CANDIDATES, WITH A TOTAL DEAL VALUE OF UP TO
USD 930 MILLION
    * HEIDELBERG PHARMA-HUADONG WILL PARTICIPATE IN A RIGHTS
ISSUE
    * HEIDELBERG PHARMA-HUADONG WILL ACQUIRE A PERCENTAGE OF
CURRENT
SHAREHOLDINGS FROM EXISTING SHAREHOLDERS INCLUDING DIEVINI,
TOTALING EUR 105 MILLION
    * HEIDELBERG PHARMA AG- HUADONG PLANS TO ACQUIRE UP TO 26%
OF
HEIDELBERG PHARMA SHARES OUTSTANDING IN CONTEXT OF RIGHTS ISSUE
    * HEIDELBERG PHARMA AG - HUADONG INTENDS TO MAKE AN EQUITY
INVESTMENT IN HEIDELBERG PHARMA TOTALING EUR 105 MILLION

Source text for Eikon:  ID:nEQ4pJN3Ra 
Further company coverage:  HPHA.DE 

 ((reuters.briefs@thomsonreuters.com;))